CytomX Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Deficit
(in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Deficit | |
| Balance at December 31, 2023 | 67,310,838 | $1 | $675,905 | $95 | $(723,448) | $(47,447) |
| Exercise of stock options and release of RSUs | 826,797 | — | 174 | — | — | 174 |
| Stock-based compensation | — | — | 1,907 | — | — | 1,907 |
| Other comprehensive loss | — | — | — | (105) | — | (105) |
| Net income | — | — | — | — | 13,791 | 13,791 |
| Balance at March 31, 2024 | 68,137,635 | 1 | 677,986 | (10) | (709,657) | (31,680) |
| Exercise of stock options and release of RSUs | 12,477 | — | 20 | — | — | 20 |
| Issuance of common stock under the ESPP | 196,930 | — | 236 | — | — | 236 |
| Issuance of common stock under the Open Market Sale Agreement, net of issuance cost | 2,270,608 | — | 4,843 | — | — | 4,843 |
| Exercise of pre-funded warrants | 7,499,951 | — | — | — | — | — |
| Stock-based compensation | — | — | 1,882 | — | — | 1,882 |
| Other comprehensive income | — | — | — | 6 | — | 6 |
| Net loss | — | — | — | — | (6,534) | (6,534) |
| Balance at June 30, 2024 | 78,117,601 | 1 | 684,967 | (4) | (716,191) | (31,227) |
| Release of RSUs | 115,000 | — | — | — | — | — |
| Stock-based compensation | — | — | 1,995 | — | — | 1,995 |
| Other comprehensive income | — | — | — | 44 | — | 44 |
| Net income | — | — | — | — | 5,736 | 5,736 |
| Balance at September 30, 2024 | 78,232,601 | $1 | $686,962 | $40 | $(710,455) | $(23,452) |
| Accumulated | ||||||
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Deficit | |
| Balance at December 31, 2022 | 66,228,046 | $1 | $637,117 | $10 | $(722,879) | $(85,751) |
| Release of RSUs | 110,892 | — | — | — | — | — |
| Stock-based compensation | — | — | 2,409 | — | — | 2,409 |
| Other comprehensive income | — | — | — | 16 | — | 16 |
| Net loss | — | — | — | — | (3,311) | (3,311) |
| Balance at March 31, 2023 | 66,338,938 | 1 | 639,526 | 26 | (726,190) | (86,637) |
| Exercise of stock options | 16,535 | — | 26 | — | — | 26 |
| Release of RSUs | 212,312 | — | — | — | — | — |
| Issuance of common stock under the ESPP | 199,994 | — | 291 | — | — | 291 |
| Stock-based compensation | — | — | 2,371 | — | — | 2,371 |
| Other comprehensive income | — | — | — | 9 | — | 9 |
| Net loss | — | — | — | — | (1,087) | (1,087) |
| Balance at June 30, 2023 | 66,767,779 | 1 | 642,214 | 35 | (727,277) | (85,027) |
| Release of RSUs | 105,000 | — | — | — | — | — |
| Issuance pre-funded warrants and warrants, net of issuance cost | — | — | 29,669 | — | — | 29,669 |
| Stock-based compensation | — | — | 1,226 | — | — | 1,226 |
| Other comprehensive loss | — | — | — | (98) | — | (98) |
| Net income | — | — | — | — | 2,992 | 2,992 |
| Balance at September 30, 2023 | 66,872,779 | $1 | $673,109 | $(63) | $(724,285) | $(51,238) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.